Sorin Pâslaru, ZF: Preluarea Biofarm de către polonezi la de patru ori cifra de afaceri şi de 12 ori profitul net este o tranzacţie la care antreprenorii locali ar trebui să fie foarte atenţi

The acquisition of Biofarm by Polish company Polpharma highlights the growing interest of Polish investors in the Romanian market, suggesting that local businesses may be undervalued. This transaction, valued at nearly 260 million euros, reflects the potential of the Romanian pharmaceutical sector, which faces a significant import deficit. Pâslaru emphasizes the importance of protecting local capital to ensure Romania's relevance in the industry. He notes that Poland's economic model and strategic partnerships have positioned it ahead of Romania, indicating a trend of increasing Polish investment in various sectors, including finance.